United States · Platforms & data · Seeking Alpha

Talphera outlines plan to seek FDA agreement to end NEPHRO enrollment by Dec. 31, 2026, while raising Niyad peak U.S. sales view to over $200M

Published by Seeking Alpha · United States 2 h ago

Read the full article on Seeking Alpha Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (seekingalpha.com)

Also worth reading

Aeva Technologies (NASDAQ:AEVA) Stock Crosses Below Fifty Day Moving Average on Insider Selling

The Motley Fool

Intuitive Machines: 3 Key Takeaways for Long-Term Investors

‘The thought of living to 100 terrifies me’: Is Social Security a giant Ponzi scheme?

RedCloud to implement 100-to-1 reverse stock split Tuesday

How the Jensen Huang affair changes the outlook for U.S.-China relations

Nvidia exit sends crypto's AI stocks tumbling